Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glass microstructure capping and bonding techniques.
Mazurczyk R, Mansfield CD, Lygan M. Mazurczyk R, et al. Among authors: mansfield cd. Methods Mol Biol. 2013;949:141-51. doi: 10.1007/978-1-62703-134-9_10. Methods Mol Biol. 2013. PMID: 23329441
Introduction to glass microstructuring techniques.
Mazurczyk R, Mansfield CD. Mazurczyk R, et al. Among authors: mansfield cd. Methods Mol Biol. 2013;949:125-40. doi: 10.1007/978-1-62703-134-9_9. Methods Mol Biol. 2013. PMID: 23329440
Correction: Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Among authors: mansfield cd. Alzheimers Res Ther. 2023 Apr 22;15(1):85. doi: 10.1186/s13195-023-01230-9. Alzheimers Res Ther. 2023. PMID: 37087449 Free PMC article. No abstract available.
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Among authors: mansfield cd. Alzheimers Res Ther. 2023 Feb 28;15(1):39. doi: 10.1186/s13195-023-01169-x. Alzheimers Res Ther. 2023. PMID: 36849969 Free PMC article. Clinical Trial.
Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial.
Davidescu L, Ursol G, Korzh O, Deshmukh V, Kuryk L, Nortje MM, Godlevska O, Devouassoux G, Khodosh E, Israel E, Moussy A, Mansfield CD, Hermine O, Chanez P. Davidescu L, et al. Among authors: mansfield cd. J Asthma Allergy. 2022 Jun 7;15:737-747. doi: 10.2147/JAA.S337284. eCollection 2022. J Asthma Allergy. 2022. PMID: 35698580 Free PMC article.
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.
Mora JS, Bradley WG, Chaverri D, Hernández-Barral M, Mascias J, Gamez J, Gargiulo-Monachelli GM, Moussy A, Mansfield CD, Hermine O, Ludolph AC. Mora JS, et al. Among authors: mansfield cd. Ther Adv Neurol Disord. 2021 Jul 19;14:17562864211030365. doi: 10.1177/17562864211030365. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34457038 Free PMC article.
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O; AB10015 STUDY GROUP. Mora JS, et al. Among authors: mansfield cd. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):5-14. doi: 10.1080/21678421.2019.1632346. Epub 2019 Jul 7. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31280619 Free article. Clinical Trial.
35 results